View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
June 10, 2020

Coronavirus company news summary – Daewoong’s niclosamide removes SARS-CoV2 from lungs in animal tests – GSK trials RA drug against Covid-19 pneumonia

By Chris Lo

10 June

South Korea-based Daewoong Pharmaceutical has found that its anti-parasitic drug niclosamide removed SARS-CoV-2, the novel coronavirus that causes Covid-19, from lungs in animal tests. The company added that the drug completely cleared the infection in ferrets’ lung tissues and inhibited inflammation, according to Reuters.

Read the full story here.

GlaxoSmithKline (GSK) has commenced a clinical trial of an experimental rheumatoid arthritis drug, otilimab, to treat patients with pneumonia caused by Covid-19 in the US. The company intends to expand the study to include patients in the UK, Italy, Spain, South America and Africa, reported Reuters.

China-based Sinovac Biotech has joined the list of the Philippines’ potential collaborators for Covid-19 vaccine development and clinical trials. Last month, Sinovac Biotech announced that the company was in talks to perform late-stage trials of its Covid-19 vaccine candidate worldwide.

Twist Bioscience has partnered with SerImmune to identify and assess anti-SARS-CoV-2 therapeutic antibody candidates. The partners will use SerImmune ‘s Serum Epitope Repertoire Analysis (Sera ) platform to analyse existing Twist antibody candidates with high affinity to bind to SARS-CoV-2 S1 spike protein or the human ACE2 cellular receptor.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology